In addition to the clinical trials in progress, drug combinations such as Dasatinib and CmpbA (IKKβ/NF-κB inhibitor) are being explored in HNSCC patients resistant to cisplatin [66]. This evidence concerns the gene IKBKB and head and neck squamous cell carcinoma.